Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q6ZMT4
UPID:
KDM7A_HUMAN
Alternative names:
JmjC domain-containing histone demethylation protein 1D; Lysine-specific demethylase 7; [histone H3]-dimethyl-L-lysine9 demethylase 7A
Alternative UPACC:
Q6ZMT4; A4D1S9; C9JJH9; C9JQU2; Q6MZL8; Q9C0E5
Background:
Lysine-specific demethylase 7A, also known as JmjC domain-containing histone demethylation protein 1D, plays a pivotal role in brain development by specifically demethylating key lysine residues on histones H3 and H4. This action is central to the histone code, influencing gene expression by modifying chromatin structure.
Therapeutic significance:
Understanding the role of Lysine-specific demethylase 7A could open doors to potential therapeutic strategies.